MCID: BNG036
MIFTS: 49

Bone Giant Cell Tumor

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Bone Giant Cell Tumor

MalaCards integrated aliases for Bone Giant Cell Tumor:

Name: Bone Giant Cell Tumor 12 15 17
Giant Cell Tumor of Bone 12 20 58 36 44 71
Osteoclastoma 12 20 58 54
Gct of Bone 20 58
Giant Cell Neoplasm of Bone 12
Giant Cell Tumour of Bone 12
Bone Giant Cell Tumour 12
Giant Cell Myeloma 12

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:4305
KEGG 36 H01470
MeSH 44 D018212
NCIt 50 C121932
SNOMED-CT 67 697970009
ICD10 via Orphanet 33 D48.0
UMLS via Orphanet 72 C0206638
Orphanet 58 ORPHA363976
UMLS 71 C0206638

Summaries for Bone Giant Cell Tumor

KEGG : 36 Giant-cell tumor of bone (GCTB) is a rare osteolytic tumor of the bone. Although classified as a benign tumor, GCTB is characterized by local aggressiveness and risk of local recurrence. Its name is derived from the numerous multinucleated giant cells found within the tumor, which are principally responsible for the extensive bone resorption that is characteristic of GCTB. However, the neoplastic components of GCTB are the spindle-like stromal cells, which produce RANKL that recruits monocytic osteoclast precursors from blood to the tumor, and stimulates differentiation into multinucleated giant cells. Recently, denosumab (RANKL inhibitor) has become a new treatment option for locally advanced GCTB.

MalaCards based summary : Bone Giant Cell Tumor, also known as giant cell tumor of bone, is related to bone giant cell sarcoma and aneurysmal bone cysts, and has symptoms including pain An important gene associated with Bone Giant Cell Tumor is ACP5 (Acid Phosphatase 5, Tartrate Resistant), and among its related pathways/superpathways are Degradation of the extracellular matrix and RANK Signaling in Osteoclasts. The drugs Denosumab and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and pancreas, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A benign giant cell tumor that results in the presence of multinucleated giant cells.

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 363976DefinitionA rare bone sarcoma characterized by a usually benign space-occupying lesion, which is nevertheless locally aggressive and massively damaging to surrounding bone tissue. The tumor is composed of giant multinucleated cells (osteoclast-like cells), mononuclear macrophages, and mononuclear stromal cells which secrete pro-myeloid and pro-osteoclastic factors. Metastasis and malignant transformation are rare, but the recurrence rate is high.Visit the Orphanet disease page for more resources.

Wikipedia : 74 Giant-cell tumor of the bone (GCTOB), is a relatively uncommon tumor of the bone. It is characterized by... more...

Related Diseases for Bone Giant Cell Tumor

Diseases related to Bone Giant Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 bone giant cell sarcoma 31.6 TNFSF11 H3-3B H3-3A CSF1
2 aneurysmal bone cysts 31.3 USP6 TNFSF11 CALCA
3 malignant giant cell tumor 31.1 H3-3B H3-3A CD68 ACP5
4 fibroma 30.8 USP6 SERPINA3 CD68
5 osteonecrosis 30.7 TNFSF11 PTH ACP5
6 chondroblastoma 30.6 USP6 TNFSF11 SERPINA3 H3-3B H3-3A
7 epulis 30.5 SERPINA3 CD68
8 mammary paget's disease 30.4 TNFSF11 PTH CALCA ACP5
9 ossifying fibroma 30.4 USP6 SH3BP2 SERPINA3 PTH
10 hyperparathyroidism 30.4 TNFSF11 PTH CALCA ACP5
11 fibrous dysplasia 30.4 TNFSF11 SPP1 SH3BP2 CALCA
12 osteomyelitis 30.2 TNFSF11 CTSK CALCA ACP5
13 bone cancer 30.2 TNFSF11 SERPINA3 PTH CALCA
14 primary hyperparathyroidism 30.2 TNFSF11 PTH CALCA
15 telangiectatic osteogenic sarcoma 30.2 USP6 H3-3B H3-3A
16 synovitis 30.1 TNFSF11 CD68 ACP5
17 bone inflammation disease 30.0 TNFSF11 SERPINA3 ACP5
18 multicentric carpotarsal osteolysis syndrome 30.0 TNFSF11 CTSK CSF1 ACP5
19 bone resorption disease 29.8 TNFSF11 SPP1 SERPINA3 PTH CTSK CSF1
20 villonodular synovitis 29.7 CSF1 CD68 ACP5
21 anaplastic astrocytoma 29.6 THBS1 SERPINA3 H3-3B H3-3A CTSB
22 malignant astrocytoma 29.5 THBS1 SPP1 SERPINA3 H3-3B H3-3A
23 osteopetrosis 29.4 TNFSF11 CTSK CSF1 CALCR CALCA ACP5
24 cherubism 29.3 USP6 TNFSF11 SH3BP2 CSF1 CALCA
25 benign giant cell tumor 29.3 TNFSF11 SERPINA3 H3-3B H3-3A CTSK CSF1
26 giant cell reparative granuloma 29.3 USP6 TNFSF11 SH3BP2 SERPINA3 PTH CD68
27 paget's disease of bone 29.3 ZNF687 TNFSF11 PTH CSF1 CALCA ACP5
28 pigmented villonodular synovitis 29.1 TNFSF11 SERPINA3 CSF1 CD68 CALCR ACP5
29 bone disease 29.1 TNFSF11 THBS1 SPP1 PTH CTSK CSF1
30 connective tissue benign neoplasm 28.4 USP6 TNFSF11 SERPINA3 PTH H3-3B H3-3A
31 paget disease of bone 6 11.2
32 osteogenic sarcoma 10.8
33 malignant fibrous histiocytoma 10.5
34 fibrous histiocytoma 10.5
35 fibrosarcoma 10.4
36 rare tumor 10.4
37 osteonecrosis of the jaw 10.3
38 kummell's disease 10.3 TNFSF11 CALCA
39 paget disease of bone 5, juvenile-onset 10.3 TNFSF11 CALCA
40 calcific tendinitis 10.3 SPP1 CTSK
41 chondrosarcoma 10.3
42 osteoblastoma 10.3
43 spindle cell sarcoma 10.3
44 47,xyy 10.3
45 rapidly involuting congenital hemangioma 10.3
46 substernal goiter 10.3 PTH CALCA
47 adult brain stem glioma 10.3 H3-3B H3-3A
48 femoral cancer 10.3 TNFSF11 ACP5
49 osteopetrosis, autosomal recessive 2 10.3 TNFSF11 CTSK ACP5
50 periapical periodontitis 10.3 TNFSF11 CTSK ACP5

Graphical network of the top 20 diseases related to Bone Giant Cell Tumor:



Diseases related to Bone Giant Cell Tumor

Symptoms & Phenotypes for Bone Giant Cell Tumor

UMLS symptoms related to Bone Giant Cell Tumor:


pain

GenomeRNAi Phenotypes related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.7 CTSB
2 Decreased viability GR00055-A-2 9.7 CTSB
3 Decreased viability GR00221-A-2 9.7 ITGAV
4 Decreased viability GR00221-A-4 9.7 THBS1
5 Decreased viability GR00249-S 9.7 ACP5 CSF1 CTSB H3-3B ITGAV SERPINA3
6 Decreased viability GR00381-A-1 9.7 CALCA CTSK ITGAV USP6 ZNF687
7 Decreased viability GR00386-A-1 9.7 ITGAV TNFSF11
8 Decreased viability GR00402-S-2 9.7 CTSK INTS13 THBS1 TNFSF11

MGI Mouse Phenotypes related to Bone Giant Cell Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 CALCR CSF1 CTSB CTSK H3-3B ITGAV
2 hematopoietic system MP:0005397 10.06 CALCR CD68 CSF1 CTSK ITGAV PTH
3 craniofacial MP:0005382 9.97 CSF1 CTSK ITGAV PTH SH3BP2 SPP1
4 immune system MP:0005387 9.93 CALCR CD68 CSF1 CTSB CTSK ITGAV
5 limbs/digits/tail MP:0005371 9.56 CALCR CSF1 CTSK PTH SH3BP2 THBS1
6 skeleton MP:0005390 9.32 CALCR CD68 CSF1 CTSK PTH SH3BP2

Drugs & Therapeutics for Bone Giant Cell Tumor

Drugs for Bone Giant Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 4 615258-40-7
2 Immunologic Factors Phase 4
3 Immunoglobulin G Phase 4
4 Immunoglobulins Phase 4
5 Antibodies Phase 4
6 Immunoglobulins, Intravenous Phase 4
7 Antibodies, Monoclonal Phase 4
8
Phenol Approved, Experimental Phase 3 108-95-2 996
9
Ethanol Approved Phase 3 64-17-5 702
10 Diphosphonates Phase 3
11 Polymethyl Methacrylate Phase 3
12
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
13
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
14
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
15
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
16
Zoledronic Acid Approved Phase 1, Phase 2 118072-93-8 68740
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 1406-16-2
18 Protein Kinase Inhibitors Phase 2
19 Immunosuppressive Agents Phase 2
20 Analgesics, Non-Narcotic Phase 2
21 Anti-HIV Agents Phase 2
22 Interleukin-2 Phase 2
23 Anti-Infective Agents Phase 2
24 Antirheumatic Agents Phase 2
25 Antiviral Agents Phase 2
26 Analgesics Phase 2
27 Alkylating Agents Phase 2
28 Anti-Retroviral Agents Phase 2
29 Calcium, Dietary Phase 1, Phase 2
30 Nutrients Phase 1, Phase 2
31 Micronutrients Phase 1, Phase 2
32 Trace Elements Phase 1, Phase 2
33 Vitamins Phase 1, Phase 2
34 Hormones Phase 1, Phase 2
35 Calciferol Phase 1, Phase 2
36 Pharmaceutical Solutions Phase 2
37
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
38
Calcium Nutraceutical Phase 1, Phase 2 7440-70-2 271
39 Calcium Supplement

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
2 An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone Not yet recruiting NCT04586660 Phase 4 XGEVA®
3 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
4 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
5 An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone Completed NCT00396279 Phase 2
6 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone Completed NCT00680992 Phase 2 Denosumab
7 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
8 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Autologous Tumor Infiltrating Lymphocytes LN-145-S1;Cyclophosphamide;Fludarabine
9 A Phase Ib/II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of JMT103 in Surgically Unsalvageable or Refractory Giant Cell Tumor of Bone Not yet recruiting NCT04255576 Phase 1, Phase 2
10 Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study Terminated NCT00889590 Phase 2 Zoledronic acid
11 Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE" Terminated NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
12 Phase 2 Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Terminated NCT01564121 Phase 1, Phase 2 acid Zoledronic
13 Giant Cell Tumor of the Bone in Patients Under 15 Years Old: a Single Institution Case-series Completed NCT04002817
14 Il Tumore a Cellule Giganti Delle estermità Completed NCT02996734
15 Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China:Correlation Between Recurrence and Drug Withdrawl Not yet recruiting NCT03358212 Denosumab

Search NIH Clinical Center for Bone Giant Cell Tumor

Cochrane evidence based reviews: giant cell tumor of bone

Genetic Tests for Bone Giant Cell Tumor

Anatomical Context for Bone Giant Cell Tumor

MalaCards organs/tissues related to Bone Giant Cell Tumor:

40
Bone, Myeloid, Pancreas, Thyroid, Lymph Node, Skin, Ovary

Publications for Bone Giant Cell Tumor

Articles related to Bone Giant Cell Tumor:

(show top 50) (show all 1142)
# Title Authors PMID Year
1
T-cell infiltration profile in musculoskeletal tumors. 61
33095470 2021
2
Malignancy in giant cell tumor of bone in the extremities. 61
33251099 2021
3
Prognostic Factors for Survival in Patients with Malignant Giant Cell Tumor of Bone: A Risk Nomogram Analysis Based on the Population. 61
33594036 2021
4
Novel Strategy of Curettage and Adjuvant Microwave Therapy for the Treatment of Giant Cell Tumor of Bone in Extremities: A Preliminary Study. 61
33442922 2021
5
Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation. 61
32773532 2021
6
Bilateral Lung Metastases From a Phalangeal Giant Cell Tumor of Bone. 61
33023391 2021
7
Utility of intraoperative magnetic resonance imaging for giant cell tumor of bone after denosumab treatment: a pilot study. 61
33517664 2021
8
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. 61
33482769 2021
9
[Analysis of the molecular penotypes and histopathological features of giant cell tumor of bone with denosumab treatment]. 61
33396989 2021
10
Preoperative Denosumab may increase the Risk of Local Recurrence of Giant-cell Tumor of Bone Treated with Curettage: A Systematic Review and Meta-analysis. 61
33391447 2021
11
Giant Cell Tumor of Bone in the Talus Treated by Extended Curettage and Synthetic Bone SubstituteReport of a Rare Case. 61
33207151 2020
12
Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone. 61
32429739 2020
13
Clinical and pathological analysis of giant cell tumor of bone with denosumab treatment and local recurrence. 61
33358447 2020
14
H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. 61
32967858 2020
15
Incidence, Management, and Outcomes of Spinal Giant Cell Tumor of Bone in Adult Patients: A National Cancer Database Analysis. 61
32853765 2020
16
Pre-operative prognostic nutritional index was associated with recurrence after surgery in giant cell tumor of bone patients. 61
33088701 2020
17
Does Osteoarticular Allograft Reconstruction Achieve Long-term Survivorship after En Bloc Resection of Grade 3 Giant Cell Tumor of Bone? 61
32469488 2020
18
CORR Insights®: Does Osteoarticular Allograft Reconstruction Achieve Long-term Survivorship after En Bloc Resection of Grade 3 Giant Cell Tumor of Bone? 61
32639310 2020
19
[The malignant transformation after denosumab-treated giant cell tumor of bone and the H3F3A mutation syndrome]. 61
33152826 2020
20
Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone? 61
32401001 2020
21
Primary Bone Tumors in North of Jordan. 61
33605114 2020
22
Outcome of lung metastases due to bone giant cell tumor initially managed with observation. 61
33160367 2020
23
CORR Insights®: Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone? 61
32732739 2020
24
The two faces of giant cell tumor of bone. 61
32502498 2020
25
Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone. 61
33110075 2020
26
[Treatment of distal tibial tumor with vascularized fibula reconstruction]. 61
33063483 2020
27
p62 overexpression promotes neoplastic stromal cell proliferation and is associated with the recurrence of giant cell tumor of bone. 61
32863919 2020
28
Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. 61
32815117 2020
29
Malignant giant cell tumor of bone or soft tissue treated by surgery with or without radiotherapy. 61
32293747 2020
30
A Rare Case Report of Chondroblastoma Pisiform in Adolescent. 61
33489960 2020
31
Mid-term results of intralesional extended curettage, cauterization, and polymethylmethacrylate cementation in the treatment of giant cell tumor of bone: A retrospective case series. 61
33155564 2020
32
Denosumab for Bone Giant Cell Tumor of the Distal Radius. 61
32745221 2020
33
Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. 61
32377818 2020
34
Can p63 serve as a biomarker for diagnosing giant cell tumor of bone? A systematic review and meta-analysis. 61
33111920 2020
35
Clinical and Radiological Profile of Ten Interesting Though Rare Presentations of Giant Cell Tumor of Bone. 61
33013139 2020
36
Functional outcome in giant cell tumor of distal radius treated with excision and fibular arthroplasty: a case series. 61
32358713 2020
37
Successful Treatment with Denosumab of a Giant Cell Tumor of Bone in the Iliac Bone of an 84-Year-Old Man. 61
32884443 2020
38
Clinical Value of Differential lncRNA Expressions in Diagnosis of Giant Cell Tumor of Bone and Tumor Recurrence. 61
32658428 2020
39
Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine. 61
32298199 2020
40
Secondary Osteoarthritis After Curettage and Calcium Phosphate Cementing for Giant-Cell Tumor of Bone Around the Knee Joint: Long-Term Follow-up. 61
32984748 2020
41
Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone. 61
32623530 2020
42
Giant Cell Tumor of Bone With Cartilage Matrix: A Clinicopathologic Study of 17 Cases. 61
32412716 2020
43
Multiple primary tumors: a case report and review of the literature. 61
32571290 2020
44
[Interpretation of 2020 NCCN Clinical Practice Guidelines in Oncology-Bone Cancer]. 61
32498481 2020
45
Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies. 61
32320927 2020
46
[Treatment of giant cell tumor of bone around knee joint with three-dimensional printing personalized prosthesis]. 61
32538567 2020
47
A case of pelvic giant cell tumor of bone, complete remission with denosumab: long duration of response. 61
31743134 2020
48
Expression of H3.3 G34W Distinguishes Giant Cell Tumor of Bone From Its Major Giant Cell-containing Bone and Soft Tissue Mimics, in Particular Aneurysmal Bone Cyst and Giant Cell Tumor of Soft Tissue. 61
29489506 2020
49
Functional Outcomes After Sauve-Kapandji Arthrodesis. 61
31948706 2020
50
CORR Insights®: Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review. 61
32187094 2020

Variations for Bone Giant Cell Tumor

Expression for Bone Giant Cell Tumor

Search GEO for disease gene expression data for Bone Giant Cell Tumor.

Pathways for Bone Giant Cell Tumor

GO Terms for Bone Giant Cell Tumor

Cellular components related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosome GO:0005764 9.72 USP6 CTSK CTSB CD68 ACP5
2 extracellular space GO:0005615 9.61 TNFSF11 THBS1 SPP1 SERPINA3 PTH CTSK
3 extracellular region GO:0005576 9.36 TNFSF11 THBS1 SPP1 SERPINA3 PTH H3-3B
4 Barr body GO:0001740 9.26 H3-3B H3-3A
5 endolysosome lumen GO:0036021 9.16 CTSK CTSB

Biological processes related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.91 THBS1 SPP1 SERPINA3 CSF1 CALCA
2 osteoblast differentiation GO:0001649 9.74 SPP1 H3-3B H3-3A
3 regulation of megakaryocyte differentiation GO:0045652 9.71 THBS1 H3-3B H3-3A
4 ossification GO:0001503 9.67 TNFSF11 THRA SPP1 ACP5
5 muscle cell differentiation GO:0042692 9.59 H3-3B H3-3A
6 response to vitamin D GO:0033280 9.58 SPP1 PTH
7 positive regulation of macrophage chemotaxis GO:0010759 9.58 THBS1 CSF1
8 osteoclast differentiation GO:0030316 9.58 TNFSF11 CSF1 CALCR
9 thyroid hormone generation GO:0006590 9.56 CTSK CTSB
10 positive regulation of macrophage differentiation GO:0045651 9.55 CSF1 CALCA
11 cellular protein metabolic process GO:0044267 9.55 SPP1 H3-3B H3-3A CSF1 CALCA
12 amylin receptor signaling pathway GO:0097647 9.52 CALCR CALCA
13 pericentric heterochromatin assembly GO:0031508 9.49 H3-3B H3-3A
14 negative regulation of dendritic cell antigen processing and presentation GO:0002605 9.48 THBS1 CD68
15 osteoclast proliferation GO:0002158 9.46 TNFSF11 CSF1
16 regulation of centromere complex assembly GO:0090230 9.43 H3-3B H3-3A
17 negative regulation of chromosome condensation GO:1902340 9.32 H3-3B H3-3A
18 telomeric heterochromatin assembly GO:0031509 9.26 H3-3B H3-3A
19 embryo implantation GO:0007566 9.26 SPP1 H3-3B H3-3A CALCA
20 bone resorption GO:0045453 8.92 TNFSF11 PTH CTSK ACP5

Molecular functions related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 ZNF687 USP6 TNFSF11 THRA THBS1 SPP1
2 cysteine-type endopeptidase activity GO:0004197 9.5 USP6 CTSK CTSB
3 extracellular matrix binding GO:0050840 9.33 THBS1 SPP1 ITGAV
4 fibronectin binding GO:0001968 9.13 THBS1 ITGAV CTSK
5 proteoglycan binding GO:0043394 8.8 THBS1 CTSK CTSB

Sources for Bone Giant Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....